Johnson & Johnson
New York Stock ExchangeCapital Structure
•
in mil. unless spec.Working Capital
•
in mil. unless spec.Growth Rates
•
in mil. unless spec.Quarterly Revenue
•
in mil. unless spec.Quarterly Earnings Per Share
•
in mil. unless spec.Quarterly Dividends Per Share
•
in mil. unless spec.Company Description
- CEO
- Joaquin Duato
- Full Time Employees
- 141,700
- Sector
- Healthcare
- Industry
- Drug Manufacturers - General
- Address
- One Johnson & Johnson Plaza New Brunswick NJ United States of America 08933
- IPO Date
- Jan 2, 1962
- CIK
- 0000200406
- Website
- jnj.com
- Similar Companies
- Business
- Johnson & Johnson is a global healthcare company engaged primarily in the research, development, manufacture, and sale of a broad range of pharmaceutical, medical device, and consumer health products. The company operates segments including Pharmaceuticals, Medical Devices, and Consumer Health, offering products such as prescription medicines for immunology, oncology, neuroscience, infectious diseases; orthopedic and surgical devices; and branded consumer healthcare products like Band-Aid and Listerine. Founded in 1886 and headquartered in New Brunswick, New Jersey, Johnson & Johnson serves customers worldwide across multiple markets. Recent major changes include Johnson & Johnson's 2025 acquisition of neurological drug maker Intra-Cellular Therapies for approximately $14.6 billion, expanding its neuroscience portfolio. In November 2025, J&J also announced the acquisition of Halda Therapeutics for $3.05 billion to bolster its oncology pipeline with innovations targeting metastatic castration-resistant prostate cancer. The company launched new cancer therapies Vykt, Tecvayli, and Talvey targeting multiple myeloma, generating $1.3 billion in sales in the first half of 2025. Furthermore, J&J is advancing drug candidates such as nipocalimab (Imaavy) for immune-mediated disorders and Caplyta for bipolar depression. The company also plans to divest its consumer health segment, signaling a strategic shift to focus more intensively on pharmaceuticals and medical devices. Johnson & Johnson continues to pursue regulatory approvals and expand indications for key drugs including SIMPONI, STELARA, TREMFYA, and Caplyta. It projects peak sales of several pipeline candidates at approximately $5 billion each. The firm remains heavily invested in research and development across immunology, oncology, neuroscience, and autoimmune diseases, leveraging innovative technologies including adenovirus vector and mRNA platforms. Johnson & Johnson reported a 6.8% sales increase to $24 billion in Q3 2025, reflecting operational growth driven by its pharmaceutical segment. This combination of advanced product portfolios, strategic acquisitions, and selective divestitures positions Johnson & Johnson as a leading global medical and pharmaceutical company focused on delivering innovative therapeutic solutions worldwide. The company's broad geographic operations span North America, Europe, Asia-Pacific, and emerging markets, catering to diverse healthcare needs across prescription drugs, medical devices, and consumer health products.
Company News
Johnson & Johnson $JNJ Stock: Cliftonlarsonallen Wealth Advisors LLC Boosts Position
Johnson & Johnson Investigation Notice: SueWallSt Notifies Investors of Pending Investigation Into Johnson & Johnson (JNJ)
These Analysts Cut Their Forecasts On Johnson & Johnson After Q3 Results
The 3-Bucket Income System Making $13,000/Month in Pure Dividends
Stock of the Day: Is this the Bottom for Johnson & Johnson?
JNJ Q3 Earnings Call Highlights Growth Outlook and MedTech Challenges
J&J Beat and Raised. The Stock Fell Anyway.
Blockbuster Drugs Come and Go. These 5 Pharma Dividend Stocks Keep Paying
5,122 Johnson & Johnson $JNJ Shares Sold by Perpetual Ltd
Johnson & Johnson shares SLIDE nearly 6% despite stronger full-year forecast
UnitedHealth vs. Johnson & Johnson: Which Stock Is the Better Buy After Q3 Earnings?
J&J raises its forecast again. CFO Joe Wolk on what's driving it
Retiring at 56 on $5,950 a Month for Life: The Portfolio Size Most People Guess Wrong
Johnson & Johnson: Keep Calm And Hold On
Johnson & Johnson (JNJ) Q3 2026 Earnings Call Transcript
Johnson & Johnson shares fall following earnings
QUICK SPARK: J&J Eyes Worst Day Since April 2025 with MedTech Miss
Johnson & Johnson Q3 Earnings: Talc Resolution Offer Impacts Earnings, MedTech Slows Growth
Surgical Precision, Sustainable Returns: Johnson & Johnson Secures its Cash Flow Runway
Why Johnson & Johnson Stock Dropped Today